Cell therapies face regulatory and manufacturing challenges long before they are accessible to patients. Even as therapies prove effective and safe, raw material and manufacturing decisions made during early development can either stall progression or rapidly accelerate it. In this webinar, we will explore traditional challenges associated with incorporation of human mesenchymal stem cells (hMSC’s) into cell therapies and the advances being made to improve clinical manufacturing readiness.